BNP Paribas Asset Management
SUPN icon

BNP Paribas Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

BNP Paribas Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.7K Sell
922
-12,703
-93% -$647K ﹤0.01% 1764
2025
Q4 		$677K Buy
13,625
+13,188
+3,018% +$641K ﹤0.01% 1219
2025
Q3 		$21K Buy
437
+15
+4% +$604 ﹤0.01% 1375
2025
Q2 		$13K Buy
+422
New +$13.5K ﹤0.01% 1689

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BNP Paribas Asset Management's SUPN Position: Q1 2026 in Review

BNP Paribas Asset Management reduced its Supernus Pharmaceuticals (SUPN) stake by 93% in Q1 2026, selling an estimated $647K and leaving 922 shares worth $47.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1764.

BNP Paribas Asset Management first reported a position in SUPN in Q2 2025 and has held it in 4 quarters since. The position peaked at $677K in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • BNP Paribas Asset Management held 922 shares of Supernus Pharmaceuticals worth $47.7K as of Q1 2026.
  • BNP Paribas Asset Management sold 12,703 Supernus Pharmaceuticals shares in Q1 2026, an estimated $647K.
  • Supernus Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1764 holding.
  • BNP Paribas Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Asset Management's Supernus Pharmaceuticals position peaked at $677K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.